Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A parable for Sorrento?
It has been very cold here recently...minus 10 Celsius!
We have hummingbirds that spend all winter here.
We have a sugar-water feeder outside all year round.
One bossy male feeds there every few hours all day.
I have to go out and bring the feeder in several times a day as the water turns to ice. I went out only to find that he was gasping, holding tight to the feeder and couldn't move his wings.
We didn't know what to do. But we put a kleenex around him and put him in a small coffee cup and took him inside to warm up. I put my hands around the cup to warm it.
His eyes were shut...he barely moved. We thought he was dead!
My wife went outside with the cup to take him to some neighbours who know more about birds than we do.
Then I heard a shriek "He flew away!"
Is SORRENTO dead? Watch it rise and fly in the new year!
HAPPY NEW YEAR TO ALL!
I am loaded up and looking forward to great Q1!
Sorrento is an investment vehicle powered by 3 engines. Covid, cancer and non-opioid pain. All 3 engines are working and are powerful!
COVISTIX leads the way for Covid products.
SEMDEXA leads the way for pain products.
ABIVERTINIB leads the way for cancer products.
All 3 products have large blockbuster potential and all 3 are followed by other large potential products.
COVISTIX sales can pave the way for ABIVERTINIB(ARDS), COVI-AMG, COVISHIELD, COVI-MSC and COVIDROPS.
SEMDEXA sales can pave the way for SP-103, SP-104, RTX(cancer pain), and RTX(arthritic pain).
ABIVERTINIB can pave the way for a dozen ADNAB(Mayo Clinic drugs, a dozen DAR-T drugs and various other ADC's and an oncolytic virus.
Sorrento is not a one trick pony.
Want to have some fun? Try to estimate the Sorrento share price if they can sell 100 million COVISTIX test kits around the world each month. Everyone will make different assumptions but many models suggest $100 is not unreasonable. THAT IS BASED ON COVISTIX ALONE. Throw in revenue from SEMDEXA and ABIVERTINIB and several other Covid products and we are looking at some very nice numbers over the next couple of years!
Pluristem today announced the failure of their phase 2 Covid ARDS trial. They tried placental derived cells. Sorrento has so far had far more encouraging results using body fat derived cells. COVI-MSC trials in the US and Brazil should report soon.
The Brazilian COVI-MSC trial is pivotal and another study with long-haul Covid patients is planned.
Abivertinib and COVI-MSC could be an important one/two punch to defeat Covid ARDS and ARDS in general.
DARPA is funding a $34 million study of a plasmid DNA approach to Covid. Here is what SmartPharm(Sorrento 100% owned) says about this technology.
" We have used our tool box to create a scalable and cost-effective solution for creating pop-up immunity in people against coronavirus that has the capability to be rapidly scaled to deliver millions of doses. Our solution starts with our novel DNA plasmid that can express protein in muscle for weeks. This plasmid will be used to express an antibody capable of binding to and neutralizing the SARS-CoV-2 virus. This type of DNA plasmid has already been produced for other products in a fully cGMP-compliant manner and at significant quantities.
We plan to combine this DNA with a new, GMP-compliant polymer solution that may significantly enhance DNA expression in skeletal muscle. This polymer has been demonstrated to have the kind of safety profile to make it appropriate for use in humans. These two components would be delivered together through a standard hypodermic needle—a standard approach typically used in vaccines. Our approach eliminates the need for electroporation devices, which are currently being used in the delivery of these types of DNA-based antibody treatments."
SIX (6) REASONS 2022 will be PIVOTAL for SORRENTO
1. ABIVERTINIB $61 Billion global market partnership(s). There will be multi-billion upfront, milestone and royalty payments. And look to the partnership partners to become the eventual buyout actors!
2. SCILEX SPINOFF. More SP-102 data is due in January. This new treatment could gross $6-10 billion annually in the US alone!. The partner is a wealthy Singapore based venture capital firm.
3. COVISTIX REVENUE STREAM. Sales have recorded in Q4 of 2021 and will ramp up in Q1 of 2022. Europe, Central and South America, Canada, Japan and the US will follow. 30 million monthly test production near term!
4. COVIDROPS, COVI-MSC, COVISHIELD, SP-102, ABIVERTINIB(cancer and Covid) news is expected in Q1 2022 as are more EUA's. SP-102 and ABIVERTINIB revenue expected in 2H of 2022.
5. ORAL MP18 based PAN-COVID ANTI-VIRAL. A peer-reviewed publication was released showing strong pan-Covid activity (including Omicron). This could enter the clinic in Q1 or Q2. A world-wide development and marketing partner might be expected. Look for something better than Merck or Pfizer's drugs!
6. In Cancer Sorrento has more than 10 fully human antibodies in the clinic or late pre-clinical(PD-1, PD-L1, CD38, CD123, CD47,BCMA, TROP2, LAG3, CTLA-4 and CD137). Allogenic DAR-T and a second generation oncolytic virus(Seprehvec) will enter the clinic as well as several additional ADNAB(Mayo Clinic) drugs.
I was glad to see the new updated corporate presentation. https://investors.sorrentotherapeutics.com/static-files/f9f8b12e-6037-4b48-b919-6d99d417698a
And big funds are buying shares! Blackrock 20.8 million:Vanguard 15.5 million:State St. 12.3 million.
***PHASE 3, close to EUA or close to market (12 programs)
1. Abivertinib NSCLC NDA filed China
2. Abivertinib NSCLC ph.3 completed US
3. PD-L1 SCLC partnered.China NDA filed for cervical cancer.
4. Erbitux biosimilar
5. Xolair biosimilar
6. Remicade biosimilar(approved in China. SRNE holds ROW rights!)
7. SP-102 sciatica + back pain. Marketing in 2H 2022.
8. RTX Osteo Arthritis
9. RTX cancer pain
10. Covi-Stix EUA application(approval in Mexico, Brazil and Europe...15 millions shipped to Mexico. WHO and Canada coming soon. DOD CRADA
11. Sofusa Enbrel phase 1b
12. Cynviloq (part of PSS lawsuit)
***PHASE 2 (13 programs)
1. Seprehvir Oncolytic virus
2. Covi-MSC EUA potential
3. Covi-AMG EUA potential DOD CRADA
4. COVIDROPS phase 2 US, UK and Mexico. EUA potential DOD CRADA
5. Covi-Track EUA pre-validation DOD CRADA
6. PD-L1 partnered
7. Herceptin delivery partnered
8. Abivertinib Lymphoma
9. Abivertinib Covid 19 EUA potential to prevent intubation Brazil and US.
10. Abivertinib prostate cancer ph.2 IND
11. Abivertinib Lupus ph.2 IND
12. Abivertinib hairy cell leukemia
13. CD47 partnered
***PHASE 1, IND filed or pre-IND (46+ programs)
1. Seprehvec Oncolytic Virus
2. CD 38 CAR-T ph.1
3. CEA CAR-T ph.1
4. CD38 DAR-T ph.1
5. BCMA DAR-T pre-IND
6. PD-L1(C/DAR-T) pre-IND
7. CyCART-19 partnered
8. Covi-GeneMab pre-IND $34 million DARPA funding
9. PD1-GeneMab pre-IND
10. ERT (Enzyme Replacement Therapy) several pre IND programs
11. IL2Teff pre-IND
12. IL2Treg pre-IND
13. Sofusa anti-PD1 and anti-CTLA4
14. TNF-a (Enbrel) ph.1
15. CTLA-4 (Yervoy)
16. CD47 ph.1 basket trial partnered
17. TROP2 IND granted in China...partnered.
18. BCMA ADC pre-IND
19. ROR1 ADC pre-IND
20. CD25 ADNAB pre-IND
21. CD20 ADNAB (Rituxan) IIT-ph.1
22. VEGF(Avastin) ADNAB IIT-ph.1
23. PD-L1 ADNAB pre-IND
24. VEGFR2 ADNAB pre-IND
25. CBD immune diseases pre-IND
26. CBD insomnia pre-IND
27. CBD Parkinsons pre-IND
28. CBD CNS diseases pre-IND
29. PD-L1 CAR-NK partnered
30. CD38 CAR-NK to be partnered
31. CD38 ADC AL Amyloidosis
32. AC0058 ph.1b lupus
33. AC0058 pre-IND MS
34. AC0939 pre-IND CNS indications
35. A166 HER2 ADC phase 1
36. Karolinska off-the-shelf DAR-NK pre-IND
37. Covid mRNA vaccine(Sofusa delivery)
38.low cost C1 based multivalent vaccine(rights to 60% of world population)...can this deal be expanded?
39. Salicyn-30 oral antiviral
40.MP18 oral antiviral MPro inhibitor
41.Combination oral antiviral drug cocktail
42.RESPISTIX Combination Covid/seasonal flu tests
43.Combination Covid/seasonal flu vaccine
44 advanced Animal Health subsidiary
45. 1,000,000+ small molecule library
46. Twenty quadrillion antibody library
FUNDING? Sorrento has invested wisely and has millions of shares of Celularity and ImmuneOncia. These are worth many hundreds of millions and the PSS binding arbitration could be settled with very large potential gains. It has many attractive programs to partner for upfront, milestone and royalty payments! The first of many EUA's are producing revenue in Mexico and Brazil. COVISTIX production ramping up to over 30 million per month near term. Outstanding ABIVERTINIB(COVID) results in Brazil and US. Giant ABIVERTINIB centered partnership(s) coming soon! And SP-102 sales will begin in 2022 with multi-billion potential. Huge portfolio AND huge assets! Sorrento is in the early days of becoming(or being acquired by...) a Big Pharma!
SIX (6) REASONS 2022 will be PIVOTAL for SORRENTO
1. ABIVERTINIB $61 Billion global market partnership(s). There will be multi-billion upfront, milestone and royalty payments. And look to the partnership partners to become the eventual buyout actors!
2. SCILEX SPINOFF. More SP-102 data is due in January. This new treatment could gross $6-10 billion annually in the US alone!. The partner is a wealthy Singapore based venture capital firm.
3. COVISTIX REVENUE STREAM. Sales have recorded in Q4 of 2021 and will ramp up in Q1 of 2022. Europe, Central and South America, Canada, Japan and the US will follow.
4. COVIDROPS, COVI-MSC, COVISHIELD, SP-102, ABIVERTINIB(cancer and Covid) news is expected in Q1 2022 as are more EUA's. SP-102 and ABIVERTINIB revenue expected in 2H of 2022.
5. ORAL MP18 based PAN-COVID ANTI-VIRAL. A peer-reviewed publication was released showing strong pan-Covid activity (including Omicron). This could enter the clinic in Q1 or Q2. A world-wide development and marketing partner might be expected. Look for something better than Merck or Pfizer's drugs!
6. In Cancer Sorrento has more than 10 fully human antibodies in the clinic or late pre-clinical(PD-1, PD-L1, CD38, CD123, CD47,BCMA, TROP2, LAG3, CTLA-4 and CD137). Allogenic DAR-T and a second generation oncolytic virus(Seprehvec) will enter the clinic as well as several additional ADNAB(Mayo Clinic) drugs.
None of us know what the S-3 is for.
If it is to secure large contracts and/or partnerships I am for it.
If it is to ward off an hostile takeover attempt I am for it.
If it is for future acquisitions I am for it.
Large contracts and/or partnerships are coming!
Hostile takeover attempts are very possible!
Future acquisitions are likely...and I like Sorrento's acquisitions track record!
Any one...or all three could occur...2022 will be a pivotal year for SRNE IMO. I am looking forward to the NEW YEAR!
IF there is an HOSTILE TAKEOVER ATTEMPT here is how CRI describes how it can be foiled by a WHITE KNIGHT or WHITE SQUIRE strategy.(Ironically the White Squire example is PSS!)
"Hostile Takeover
A hostile takeover happens when a company attempts a takeover of another company without the approval of the target’s board of directors. A hostile takeover is usually done through:
The acquirer purchasing enough stock shares to gain a controlling interest in the target company.
The acquirer persuading existing shareholders to vote out the board of directors and replace them with a new board that is more receptive to the takeover.
White Knight in a Hostile Takeover Situation
A black knight is associated with an acquirer company that is attempting a hostile takeover of a target company. The relationship between the white knight, target company, and black knight is as follows:
Company A approaches Company B (target company) with a bid offer to purchase the company.
Company B (target company) rejects the bid offer.
After its offer is rejected, Company A attempts a hostile takeover of Company B. It is now cast in the role of a black knight.
Company C sees that Company B (target company) is undergoing a hostile takeover attempt by Company A.
Company C offers to buy Company B by offering better takeover terms and a promise to retain the current management team and preserve the company’s core business. It is now acting as a white knight.
A white knight takeover is the preferred option over a hostile takeover by a black knight.
White Knight and White Squire
A white squire is similar to a white knight. Both terms refer to an investor or company that is helping a company reject a hostile takeover.
The only difference is that a white squire, rather than acquiring the target company, purchases just enough shares of the target company to stop a hostile takeover. A white squire does not intend to take over the company and typically sells their shares after the black knight abandons its takeover attempt.
Example of White Squire
In May of 2016, Gannett Co. made a takeover bid for Tribune Publishing Co. The takeover bid was $12.25 per share in cash, worth about $820 million. The management team of Tribune declined the bid, deciding that the price understated the true value of the company and was not in the best interest of its shareholders.
Despite the rejection of their takeover bid, Gannett said it was committed to pursuing the deal and attempted a proxy fight. Gannett urged shareholders of Tribune to withhold their votes during Tribune’s annual meeting to send a message to the board of Tribune to seriously consider its offer.
In May of 2016, billionaire Patrick Soon-Shiong invested $70.5 million in Tribune. By doing so, he became the company’s second-largest shareholder. The billionaire was deemed a white squire for purchasing a large number of shares to help fend off Gannett Co’s takeover attempt."
Well I must say that is the most positive post I have ever seen you write!
The FDA is sadly very beholden to Big Pharma. Look at the very poor tests from Abbott that they approved. Or Biogen's very dangerous Alzheimers drug(voted DOWN by expert panel) which they then approved!
As in everything BIG MONEY rules.
Sorrento has made good progress on SEMDEXA and ABIVERTINIB. Those are both blockbuster drugs...and they have many more in the pipeline.If you don't understand Biotech it is a good time to buy bank stocks!
Whineylady...but they can get COVISTIX sold in Mexico. Brazil, Europe and the surrounding markets which are 3 times the size of the US market. What does does that tell you about the FDA?
I really don't care what the share price is year end 2021.
I fully expect it to be triple digits by year end 2022.
And a lot sooner than that if there is a hostile bidder!
Here are some reasons I like Sorrento.
1. SEMDEXA
2. SP-103
3. SP-104
4. RTX cancer pain
5. RTX arthritic pain
6. COVISTIX
7. COVI-AMG
8. COVI-SHIELD
9. COVIDROPS
10. COVI-MSC
11. MP-18
12. ABIVERTINIB-ARDS
13. ABIVERTINIB-cancer
14. ADNAB(Mayo Clinic)
15. DAR-T
16. SOFUSA
HAPPY NEW YEAR TO ALL THE UNMUTED!
WHAT is the $5 Billion for? Part of the partnering dance? Defence against hostile takeover threat? Here is the summary of what Sorrento is doing...
"At our core, we are antibody-centric and leverage our proprietary G-MAB™ library and targeted delivery modalities to generate the next
generation of cancer therapeutics. Our fully human antibodies include PD-1, PD-L1, CD38, CD123, CD47, BCMA, LAG3, CTLA-4, CD137 and SARSCoV-2 neutralizing antibodies, among others. We also have programs assessing the use of our technologies and products in pain, autoimmune,
inflammatory, viral and neurodegenerative diseases.
Our vision is to leverage these antibodies in conjunction with proprietary targeted delivery modalities to generate the next generation of cancer
therapeutics. These modalities include proprietary chimeric antigen receptor T-cell therapy, or CAR-T, dimeric antigen receptor T-cell therapy, or DART™, antibody drug conjugates, or ADCs, as well as bispecific antibody approaches. We acquired SOFUSA
®, a drug delivery technology, in July 2018,
which delivers biologics or other drugs directly into the lymphatic system to potentially achieve improved efficacy and reduce adverse effects compared to
standard parenteral therapy. Additionally, our majority-owned subsidiary, Scilex Holding Company, or Scilex Holding, acquired the assets of Semnur
Pharmaceuticals, Inc., or Semnur, in March 2019. Semnur’s SEMDEXA
TM, or SP-102, compound has the potential to become the first U.S. Food and Drug
Administration, or FDA,-approved epidural steroid product for the treatment of sciatica. In response to the global SARS-CoV-2, or COVID-19, pandemic,
we are utilizing the Bruton’s tyrosine kinase, or BTK, inhibitor (Abivertinib, acquired from ACEA Therapeutics, Inc.) to treat the cytokine storm associated
with a COVID-19 infection. We are also internally developing and conducting clinical studies for potential coronavirus antiviral therapies and vaccines,
including COVI-MSC™, COVI-AMG™, COVIDROPS™, and COVISHIELD™; and diagnostic test solutions, such as COVISTIX™.
With each of our clinical and preclinical programs, we aim to tailor our therapies to treat specific stages in the evolution of a disease, from
elimination to equilibrium and escape. In addition, our objective in our immuno-oncology programs is to focus on tumors that are resistant to current
treatments and where we can design focused trials based on a genetic signature or biomarker to ensure patients have the best chance of a durable and
significant response. We have several immuno-oncology programs that are in or near to entering the clinic. These include cellular therapies, oncolytic
viruses (SeprehvecTM) and a palliative care program targeted to treat intractable pain in advanced cancer and osteoarthritis (resiniferatoxin, or RTX). Our
cellular therapy programs focus on our allogeneic DAR-T platform for adoptive cellular immunotherapy to treat both solid and liquid tumors.
From the start of the COVID-19 pandemic, our mission has been in part to leverage our deep expertise in developing targeted antibodies for
cancer immunotherapy to create best-in-category treatments and diagnostics to ease suffering and assist in the global response to COVID-19. We have
leveraged, and continue to leverage, our G-MAB library and antibody development engineering capabilities to advance promising diagnostics and
neutralizing antibody candidates to test and treat COVID-19 and the immune reactions associated with SARS-CoV-2 infection.
STI-2020, or plutavimab, is a highly potent neutralizing antibody, or nAb, directed against SARS-CoV-2 that is currently being developed as an
intranasal instillation as STI-2099, or COVI-DROPS. STI-2020, the intravenous, or IV, formulation and COVI-DROPS were both cleared by the FDA for
Phase I healthy volunteer studies, which were completed and demonstrated that the nAbs were well-tolerated (IV up to 200 mg and intranasal up to 60 mg)
without dose limiting toxicity or severe or serious adverse events. Most adverse events were mild and not treatment related. Phase II studies of COVIDROPS in outpatients with COVID-19 have begun enrollment in the U.S. and the United Kingdom and enrollment in Mexico is expected to commence in
Q1 2022. The UK study is expected to reach the planned interim analysis threshold in late January 2022. The study in Mexico is anticipated to begin
pediatric enrollment in early 2022. We are also developing a cocktail of STI-2020 and STI-9167 (a second, independently developed nAb) (COVISHIELD™) to be formulated both for IV and intranasal administration, which in preclinical studies has been broadly effective against emerging variants of
concern. A healthy subject study for STI-9167 (IV formulation) and STI-9199 (intranasal formulation) is expected to begin in early Q1 2022 with Phase II
studies of COVI-SHIELD to follow.
We have also developed two promising potential rescue treatments with Abivertinib (STI-5656), an oral next generation dual EGFR, or epidermal
growth factor receptor, mutants/BTK inhibitor, to treat hospitalized COVID-19 patients and COVI-MSC (samtonadstrocel or STI-8282), human allogeneic
adipose-derived mesenchymal stromal cells, for patients suffering from COVID-19-induced acute respiratory distress. Both have been cleared by the FDA
for Phase II studies and we have completed Phase II clinical studies in the U.S. and Brazil of Abivertinib to treat COVID-19-induced acute respiratory
distress syndrome, or ARDS. While all patient groups improved with treatment, the U.S. study identified an at-risk population who were the best
responders: those who required oxygen supplementation with non-invasive ventilation or high flow oxygen at baseline. While the Brazil study did not
enroll a population as sick as those in the U.S. study, the results were similarly supportive. In the U.S. study, the at-risk patients treated with Abivertinib
were discharged from the ICU on average two days sooner than those patients that received the standard of care and placebo. In both the Brazil and U.S.
studies, there was nearly a 50% reduction of death and/or mechanical ventilation or extracorporeal membrane oxygenation in the Abivertinib treated patient
group by day 29 as compared to the placebo group. These data were used to power a pivotal Phase III Abivertinib study, which is expected to begin
enrollment in Q2 2022. Two separate COVI-MSC studies are currently enrolling in Brazil (pivotal trial) and in the U.S. (Phase II) for patients with
COVID-19-induced ARDS. We are also working with Brazilian regulators (ANVISA) to conduct a COVID-19 study with COVI-MSC in pulmonary longhaul patients post recovery from the acute infection.
In furtherance of our goal to develop products across the entire continuum of COVID-19 solutions, we are further developing highly sensitive and
rapid diagnostic tests. COVISTIX™ is a lateral flow antigen test that uses a proprietary platinum-based colloid and antibody combination, resulting in high
sensitivity and accuracy. This is a simple and rapid (15-minute) test with a nasal swab and is designed for point-of-care and at-home use. This product has
been approved for use in Mexico and Brazil as a point-of-care test and also has received its CE mark.
We previously reported early data from Phase I trials of our carcinoembryonic antigen, or CEA,-directed CAR-T program. We treated five patients
with stage 4, unresectable adenocarcinoma (four with pancreatic and one with colorectal cancer) and CEA-positive liver metastases with anti-CEA CAR-T.
During 2021, we decided to pivot away from an autologous CAR-T platform to allogeneic DAR-T (dimeric antigen receptor T cell) and successfully
submitted an Investigational New Drug application, or IND, for our CD38 DAR-T candidate for relapsed or refractory multiple myeloma, or RRMM, and
obtained FDA clearance in August 2021. We anticipate the first patient to be enrolled in early Q1 2022.
We also successfully submitted INDs for our anti-CD47 mAb (STI-6643), TROP2 ADC, or STI-3286, and Seprehvec™, or STI-1386, our secondgeneration oncolytic virus. We dosed the first patient in a Phase 1b study with STI-6643 and are awaiting follow-up data. A parallel study is also planned
for STI-6643 in China. We anticipate the first patient to be enrolled in the U.S. study with our anti-TROP2 ADC in Q1 2022. This ADC has a drug payload
SN38 (a DNA polymerase inhibitor) targeting various solid tumors. Unlike other anti-TROP2 ADC products on the market, ours has a stable covalent
linker that is designed to prevent premature release of the toxin to avoid its toxicity. Our TROP-2 ADC also has been approved for clinical trials in China
by our partner and is expected to soon enroll the third cohort. Finally, we anticipate the first patient to be enrolled in the Seprehvec study in Q1 2022.
Additionally, based upon our exclusive licensing arrangement with Mayo Clinic for its antibody-drug-nanoparticle albumin-bound (ADNAB™)
platform, the next generation in ADC technology, we intend to file several INDs to treat various cancer targets. With respect to Abivertinib, our oral small
molecule combined EGFR mutants/BTK inhibitor, we are waiting for a final imaging read of Phase III data with additional follow-up from patients who
continued on treatment in the years since the last update presented at the 2019 American Society of Clinical Oncology annual meeting. We anticipate
requesting a pre-new drug application, or NDA, meeting with the FDA to discuss the pathway to a planned NDA filing. Finally, we intend to start studies in
castrate resistant prostate cancer with Abivertinib in the U.S. in Q1 2022 and in Brazil in Q2 2022.
With respect to our anti-CD38 ADC program, we began enrolling patients in the first quarter of 2021 in a Phase Ib ascending dose study for
systemic Amyloid light-chain amyloidosis. We intend to start a new study to target RRMM in Q1 2022 and are planning to target metastatic esophageal and
lung cancer to treat T-cell acute lymphoblastic leukemia. We also have an ongoing partnership with Mayo Clinic to explore the use of lymphatic delivery
using our SOFUSA microneedle array device. Lymphatic delivery of products traditionally delivered by IV administration has the potential to improve the
pharmacokinetic profile and efficacy while reducing their adverse events profile. We also have an active program using the SOFUSA delivery system to
treat rheumatoid arthritis patients resistant to etanercept and expect to announce preliminary results from an ongoing Phase I study in Q1 2022.
Broadly speaking, we believe we are one of the world’s leading cellular therapy companies today due to our investments in technology and
infrastructure, which have enabled significant progress in developing our next-generation non-viral, “off-the-shelf” allogeneic DAR-T solutions. With such
solutions, DAR-T therapy can become a versatile drug product platform capable of delivering multiple targeted therapeutic approaches.
Outside of immuno-oncology programs, as part of our global aim to provide a wide range of therapeutic products to meet underserved markets, we
have made investments in non-opioid pain management. These include RTX, a non-opioid naturally-occurring chemical that specifically targets transient
receptor potential vanilloid-1, or TRPV1. Depending on the site of injection, RTX can ablate or destroy targeted nerves (e.g., an epidural injection) or
temporarily defunctionalize them (peripheral injections such as intra-articular). TRPV1 largely is responsible for the noxious chronic and inflammatory
pain signaling that can occur post trauma but leaves other nerve functions intact. RTX has been granted orphan drug status for the treatment of intractable
pain with end-stage or advanced cancer and two Phase Ib first-in-human trials (intrathecal and epidural routes) were completed. A Phase Ib trial studying
the safety and efficacy of RTX to treat moderate to severe osteoarthritis, or OA, knee pain was completed in early 2021 with one year follow-up data and
preliminary results showing the potential for long-term efficacy with no dose limiting toxicity. We have received clearance to proceed with Phase II clinical
trials of RTX to treat severe cancer pain (epidural) and moderate-to-severe OA of the knee pain (intra-articular). The knee OA study began enrolling in Q4
2021 and the epidural cancer pain study is expected to start enrolling in Q1 2022.
Also, in this area, we have developed in-house and acquired proprietary technologies to responsibly develop next generation, branded
pharmaceutical products to better manage patients’ medical conditions, maximize the quality of life of patients and assist healthcare providers. The flagship
product of Scilex Holding, ZTlido® (lidocaine topical system 1.8%), is a next-generation lidocaine delivery system, which was approved by the FDA for
the treatment of postherpetic neuralgia, a severe neuropathic pain condition in February 2018, and was commercially launched in October 2018. Scilex
Holding has built a full commercial organization, which includes sales, marketing, market access and medical affairs.
Recent Developments
On December 9, 2021, Scilex Holding announced highly statistically significant positive top-line results from its Phase III SP-102 (SEMDEXA™)
Pivotal Trial C.L.E.A.R Program for its novel, non-opioid, corticosteroid formulation, injectable dexamethasone sodium phosphate viscous gel product for
the treatment of lumbosacral radicular pain (sciatica). SEMDEXA has received Fast Track status from the FDA.
The C.L.E.A.R. Program trial met the primary efficacy and key secondary efficacy endpoints:
· For the primary endpoint of change in average daily pain (as measured by the Numeric Pain Rating Scale) in the affected leg over 4 weeks
following the initial injection the LS Mean (SE) group difference of -1.08 (0.17) compared to placebo with a p-value <0.001.
· The two key secondary endpoints assessing Oswestry Disability Index (ODI) and Time to open-label repeat injection have also demonstrated
highly statistically significant results for SP-102. The LS Mean (SE) group difference in ODI compared to placebo at week 4 was -6.28 (1.49) with
a p-value <0.001. A Cox proportional hazard model showed significantly longer duration of initial SP-102 (SEMDEXA™) treatment compared to
placebo Hazard Ratio (95% CI) 0.49 (0.36, 0.65), with a p-value <0.001.
For a complete description of our business, financial condition, results of operations and other important information, we refer you to our filings..."
Merry Christmas to all. I'd like to share with you part of the Bidding Prayer from a Christmas Eve service held at Cambridge University in 1918. This service was held 6 weeks after WW1 ended and in the midst of the "spanish" flu. It was written by a chaplain who had served in the trenches.
"And because this of all things would most rejoice his heart, let
us at this time remember in his name the poor and the
helpless, the cold, the hungry and the oppressed; the sick
in body and in mind and them that mourn; the lonely and
the unloved; the aged and the little children; all who know
not the Lord Jesus, or who love him not, or who by sin
have grieved his heart of love.
Lastly, let us remember before God all those who rejoice
with us, but upon another shore and in a greater light, that
multitude which no man can number, whose hope was in
the Word made flesh, and with whom, in this Lord Jesus,
we for evermore are one."
Central and South America have a combined population of over 600 million. Europe is over 700 million. Sorrento has potential markets over 3 times the size of the US market. Manufacturing and marketing must be ramped up. But meanwhile Abivertinib, SEMDEXA, COVI-AMG, COVIDROPS and COVI-MSC are advancing with more news due anytime now and into Q1 of 2022. These are the BIG DEAL!
Israel is offering a 4th vaccine shot to those over 60 and others at high risk. There is room for longer lasting vaccinations. Many of my other vaccinations are good for 5-10 years! Can Sorrento come up with a better second generation vaccine or will we hear something about the DARPA $34 million project soon. DARPA and the Navy can help with approvals! We have not heard much about these programs recently...the military and Sorrento don't like leaks...but there is clearly a need both in the military and around the world. And Sorrento has more COVID programs than any other company in the world. They are becoming a center of excellence.
https://www.msn.com/en-ca/news/world/israel-recommends-fourth-covid-19-dose-for-people-over-60-as-it-enters-the-throes-of-a-fifth-wave/ar-AAS2eKU?ocid=msedgdhp&pc=U531
I expect SEMDEXA, Abivertinib, COVI-AMG, COVIDROPS and COVI-MSC all will be approved in Mexico, Brazil, Europe and even the US in 2022.
That is why I expect a triple digit Sorrento share price in 2022.
When in 2022? The sooner the approvals, the sooner the revenue, the sooner the dramatic increase in Sorrento share price.
As a retail investor I don't know what is going on inside the company...but I like my chances. There will be partnerships. They may even be followed by a buyout...but not for less than triple digits IMO!
Will Santa bring Sorrento investors news before Christmas? I don't know but I do know there is a lot of news coming in Q1 of the New Year!
FIVE (5) REASONS SORRENTO SHAREPRICE COULD RISE IN EARLY 2022!
1. ABIVERTINIB $61 Billion global market partnership(s). There will be multi-billion upfront, milestone and royalty payments. And look to the partnership partners to become the eventual buyout actors!
2. SCILEX SPINOFF. SP-102 fuller data is due next month. This new treatment could gross $6-10 billion annually. The partner is a wealthy Singapore based venture capital firm.
3. COVISTIX REVENUE STREAM. Sales are recording in Q4 of 2021 and will ramp up in Q1 of 2022. Europe, Central and South America, Canada, Japan and the US will follow.
4. COVI-AMG, COVIDROPS, COVI-MSC, SP-102, ABIVERTINIB(cancer and Covid) news is expected in Q1 2022 as are more EUA's. SP-102 and ABIVERTINIB revenue expected in 2H of 2022.
5. ORAL MP18 based PAN-COVID ANTI-VIRAL. A peer-reviewed publication was released showing strong pan-Covid activity (including Omicron). This could enter the clinic in Q1 or Q2. A world-wide development and marketing partner might be expected. Look for something better than Merck or Pfizer's drugs!
Investors say "SHOW US THE MONEY"...and that will happen big time in 2022!
Have a look at the latest updated corporate presentation. https://investors.sorrentotherapeutics.com/static-files/f9f8b12e-6037-4b48-b919-6d99d417698a
And big funds are buying shares! Blackrock 20.8 million:Vanguard 15.5 million:State St. 12.3 million.
***PHASE 3, close to EUA or close to market (13 programs)
1. Abivertinib NSCLC NDA filed China
2. Abivertinib NSCLC ph.3 completed US
3. PD-L1 SCLC partnered.China NDA filed for cervical cancer.
4. Erbitux biosimilar
5. Xolair biosimilar
6. Remicade biosimilar(approved in China. SRNE holds ROW rights!)
7. SP-102 sciatica + back pain. Marketing could occur in 2H 2022.
8. RTX Osteo Arthritis
9. RTX cancer pain
10. Covi-Stix EUA application(approval in Mexico, Brazil and Europe...millions shipped to Mexico. WHO and Canada coming soon. DOD CRADA
11. Covi-Trace EUA application
12. Sofusa Enbrel phase 1b
13. Cynviloq (part of PSS lawsuit)
***PHASE 2 (13 programs)
1. Seprehvir Oncolytic virus
2. Covi-MSC EUA potential
3. Covi-AMG EUA potential DOD CRADA
4. COVIDROPS phase 2 US, UK and Mexico. EUA potential DOD CRADA
5. Covi-Track EUA pre-validation DOD CRADA
6. PD-L1 partnered
7. Herceptin delivery partnered
8. Abivertinib Lymphoma
9. Abivertinib Covid 19 EUA potential to prevent intubation Brazil and US.
10. Abivertinib prostate cancer ph.2 IND
11. Abivertinib Lupus ph.2 IND
12. Abivertinib hairy cell leukemia
13. CD47 partnered
***PHASE 1, IND filed or pre-IND (46+ programs)
1. Seprehvec Oncolytic Virus in phase 1b
2. CD 38 CAR-T ph.1
3. CEA CAR-T ph.1
4. CD38 DAR-T ph.1
5. BCMA DAR-T pre-IND
6. PD-L1(C/DAR-T) pre-IND
7. CyCART-19 partnered
8. Covi-GeneMab pre-IND $34 million DARPA funding
9. PD1-GeneMab pre-IND
10. ERT (Enzyme Replacement Therapy) several pre IND programs
11. IL2Teff pre-IND
12. IL2Treg pre-IND
13. Sofusa anti-PD1 and anti-CTLA4
14. TNF-a (Enbrel) ph.1
15. CTLA-4 (Yervoy)
16. CD47 ph.1 basket trial partnered
17. TROP2 IND granted in China...partnered.
18. BCMA ADC pre-IND
19. ROR1 ADC pre-IND
20. CD25 ADNAB pre-IND
21. CD20 ADNAB (Rituxan) IIT-ph.1
22. VEGF(Avastin) ADNAB IIT-ph.1
23. PD-L1 ADNAB pre-IND
24. VEGFR2 ADNAB pre-IND
25. CBD immune diseases pre-IND
26. CBD insomnia pre-IND
27. CBD Parkinsons pre-IND
28. CBD CNS diseases pre-IND
29. PD-L1 CAR-NK partnered
30. CD38 CAR-NK to be partnered
31. CD38 ADC AL Amyloidosis
32. AC0058 ph.1b lupus
33. AC0058 pre-IND MS
34. AC0939 pre-IND CNS indications
35. A166 HER2 ADC phase 1
36. Karolinska off-the-shelf DAR-NK pre-IND
37. Covid mRNA vaccine(Sofusa delivery)
38.low cost C1 based multivalent vaccine(rights to 60% of world population)...can this deal be expanded?
39. Salicyn-30 oral antiviral
40.MP18 oral antiviral MPro inhibitor
41.Combination oral antiviral drug cocktail
42.RESPISTIX Combination Covid/seasonal flu tests
43.Combination Covid/seasonal flu vaccine
44 advanced Animal Health subsidiary
45. 1,000,000+ small molecule library
46. Twenty quadrillion antibody library
FUNDING? Sorrento has invested wisely and has millions of shares of Celularity and ImmuneOncia. These are worth many hundreds of millions and the PSS binding arbitration could be settled with very large potential gains. It has many attractive programs to partner for upfront, milestone and royalty payments! The first of many EUA's are producing revenue in Mexico. Outstanding ABIVERTINIB(COVID) results in Brazil and US. Giant ABIVERTINIB centered partnership(s) coming soon! And SP-102 sales could begin in 2022 with multi-billion potential. Huge portfolio AND huge assets! Sorrento is in the early days of becoming(or being acquired by...) a Big Pharma!
I know they have to see the safety and efficacy of second generation oncolytic virus Seprehvec in monotherapy...but I look forward to seeing it combined with a second generation systemic anti-CTLA4! This could be amazing! And I wonder how it might work with Abivertinib...a true wonder drug!
I am one of many Sorrento investors who got into the stock because of its cancer treatment and cancer pain programs. I am glad to see this oncolytic virus program progress. Abivertinib is very close to approval and there are about a dozen ADNAB(Mayo Clinic) drugs and another dozen DAR-T drugs that have great promise!
SEMDEXA and RTX are progressing well in the pain portfolio...The Scilex IPO will produce more revenue on top of the recent deal with Vickers Vantage.
The Covid portfolio will soon have a great deal of news. COVISTIX revenue is increasing and there will soon be COVI-AMG, COVIDROPS and COVI-MSC results. And I look forward to more Covid antiviral news in Q1.
Exciting times...2022 is the pivotal year for Sorrento IMO!
On Dec. 5 Sorrento announced that they were in the late stage of the pre-clinical phase of oral MP18 anti-viral against all Covid variants including OMICRON!
" “We are pleased to work with Prof. Liu’s group at Texas A&M University to develop a more effective oral MPro inhibitor to meet the urgent need for treatment of COVID-19 patients infected with existing and emerging variants. The oral MPro inhibitor together with Sorrento’s other ongoing therapeutic intervention approaches reflect our efforts to create a ‘mutation-agnostic’ global anti-COVID strategy to combat COVID-19 variants of concern, including the emerging Omicron variant,” stated Dr. Henry Ji, Chairman and CEO of Sorrento."
I expect a clinical trial in Q1 of 2022.
I would not be surprised if 2 or 3 of the Big Pharma would like to partner for the $62 billion market Abivertinib potential. A bidding war would result in a sweet partnership for Sorrento. May hear soon!
Does Big Pharma have many resources to do a deal with Sorrento centered on ABIVERTINIB? I just read this about the potential for 2020 being a record year for M&A...$500 billion in cash and $1.7 trillion in leveraged assets can do a lot of deals! Partnerships and buyouts will abound IMO.
"Merger and acquisition activity has been rather slow in the biopharma industry so far this year. But, by one team of analysts’ calculations, large drugmakers will have big piles of cash to deploy in 2022.
Eighteen large-cap U.S. and European biopharmas will have more than $500 billion in cash on hand by the end of 2022, SVB Leerink analyst Geoffrey Porges and his team wrote in a Wednesday note. The companies could use the money to strike deals, pay down debt or offer returns to shareholders through dividends or share buybacks, the analysts said.
Because the companies can leverage their assets to borrow additional capital, the theoretical firepower of the 18 drugmakers would be enormous at more than $1.7 trillion, the analysts wrote..."
QUESTION: WHICH OF THESE COULD HAVE MULTI-BILLION DOLLAR SALES?
1. SEMDEXA sciatica
2. SP-103 lower back pain
3. SP-104 fibromyalgia
4. COVISTIX
5. COVI-AMG
6. COVI-DROPS
7. COVI-MSC
8. MP18 antiviral
9. ABIVERTINIB (cancer and Covid)
10. ADNAB (Mayo Clinic) cancer drugs
ANSWER: ALL OF THE ABOVE IMO!
SP-104 for fibromyalgia is in the clinic THIS month and SP-103 for lower back pain is into phase 2 NEXT month! Two huge indications!
Scilex potential is enormous. SP-103 and SP-104 have large markets. SEMDEXA has at least $3-5 billion potential in US alone for sciatica plus 10 potential uses outside of sciatica(knee, shoulder, wrist, ankle, joints) with an additional upside of 50-200%!
https://investors.sorrentotherapeutics.com/node/12901/html#tm2135241d1_ex99-1.htm
This UK analysis of Sorrento is not perfect but it is one of the best. Well worth a look!
https://img1.wsimg.com/blobby/go/7a36d2bd-679b-4c8e-b6ac-96260317c670/Sorrento%20Therapeutics%20Analysis%20-0009.pdf
Sorrento's antiviral MP18 is up to 10 times as effective as Merck's antiviral(EIDD-2801...Molnupiravir)!
"MPI8 demonstrated approximately ten-fold (10x) higher antiviral potency than EIDD-2801 against SARS-CoV-2 and its Alpha (UK) and Delta (Indian) VoCs and three to seven-fold (3-7x) higher antiviral potency against Beta (South Africa, 3X) and Gamma (Brazil/Japan, 6-7X) VoCs.."
COVI-AMG 2 minute injection news ANY DAY NOW.
A 280 inpatient trial in US has OCT.2021 completion date.
A 500 outpatient trial in US has a Nov. 2021 completion date.
COVIDROPS(the same drug sprayed up the nose) will follow shortly.
A 350 outpatient trial in the UK has a Mar.2022 completion date.
A 72 patient US study has a June 2022 completion date.
If the 2 minute injection works it is EUA time!
If the nose drops works it is another EUA in many juridictions!
Sorrento has said...
"The UK study will complement Phase 2 trials currently being started in the US and should the results of these studies demonstrate that COVIDROPS is both safe and effective against SARS-CoV-2, Sorrento will apply for Emergency Use Authorization in the US, UK, Canada, India, Mexico and European Union as well as other territories."
What's going on?
Sorrento released a "teaser" about the upcoming $61 Billion market Abivertinib PARTNERSHIP.
They released a "teaser" about the $10 Billion market Sp-102 investment by big money from Singapore.
They released a "teaser" about the powerful oral anti-viral soon going into the clinic.
They released a "teaser" about the $10 Billion potential painkiller RTX.
More partnerships? Potential buyers? Too much good news for nothing to be happening!
This is worth reading... overview of Sorrento...
....https://img1.wsimg.com/blobby/go/7a36d2bd-679b-4c8e-b6ac-96260317c670/Sorrento%20Therapeutics%20Analysis%20-0008.pdf
IT'S HAPPENING! FIVE (5) REASONS SORRENTO SHAREPRICE WILL RISE!
1. ABIVERTINIB $61 Billion global market partnership(s). There will be multi-billion upfront, milestone and royalty payments. And look to the partnership partners to become the eventual buyout actors!
2. SCILEX SPINOFF. Great SP-102 data out! This new treatment could gross $6-10 billion annually. The Scilex partner is a wealthy Singapore based venture capital firm.
3. COVISTIX REVENUE STREAM. Sales are recording in Q4 of 2021 and will ramp up in Q1 of 2022. Europe, Central and South America, Canada, Japan and the US will follow.
4. COVI-AMG, COVIDROPS, COVI-MSC, SP-102, ABIVERTINIB(cancer and Covid) news is expected in Q1 2022 as are more EUA's. SP-102 and ABIVERTINIB revenue expected in 2H of 2022.
5. ORAL MP18 based PAN-COVID ANTI-VIRAL. A peer-reviewed publication was released showing strong pan-Covid activity (including Omicron). This could enter the clinic in Q1 or Q2. A world-wide development and marketing partner might be expected. Look for something better than Merck or Pfizer's drugs!
More than 40% of opioid prescriptions are for back pain!
70% of overdose deaths are opioid related.
Lives will be saved!
WOW. 30 million people in US alone suffer from lower back pain and/or sciatica.
Market potential $6-10 Billion.
Fast Track will speed up approval...applying for Breakthrough Designation.
No safety risks.
Will help contain opioid death epidemic!
WIN! WIN! WIN! WIN!
FIVE (5) REASONS SORRENTO SHAREPRICE WILL RISE!
1. ABIVERTINIB $61 Billion global market partnership(s). There will be multi-billion upfront, milestone and royalty payments. And look to the partnership partners to become the eventual buyout actors!
2. SCILEX SPINOFF. SP-102 data is due next month. This new treatment could gross $6-10 billion annually. The partner is a wealthy Singapore based venture capital firm.
3. COVISTIX REVENUE STREAM. Sales are recording in Q4 of 2021 and will ramp up in Q1 of 2022. Europe, Central and South America, Canada, Japan and the US will follow.
4. COVI-AMG, COVIDROPS, COVI-MSC, SP-102, ABIVERTINIB(cancer and Covid) news is expected in Q1 2022 as are more EUA's. SP-102 and ABIVERTINIB revenue expected in 2H of 2022.
5. ORAL MP18 based PAN-COVID ANTI-VIRAL. A peer-reviewed publication was released showing strong pan-Covid activity (including Omicron). This could enter the clinic in Q1 or Q2. A world-wide development and marketing partner might be expected. Look for something better than Merck or Pfizer's drugs!
Investors say "SHOW US THE MONEY"...and that will happen big in 2022!
I was glad to see the new updated corporate presentation. https://investors.sorrentotherapeutics.com/static-files/f9f8b12e-6037-4b48-b919-6d99d417698a
And big funds are buying shares! Blackrock 20.8 million:Vanguard 15.5 million:State St. 12.3 million.
***PHASE 3, close to EUA or close to market (13 programs)
1. Abivertinib NSCLC NDA filed China
2. Abivertinib NSCLC ph.3 completed US
3. PD-L1 SCLC partnered.China NDA filed for cervical cancer.
4. Erbitux biosimilar
5. Xolair biosimilar
6. Remicade biosimilar(approved in China. SRNE holds ROW rights!)
7. SP-102 sciatica + back pain. Marketing in 2H 2022.
8. RTX Osteo Arthritis
9. RTX cancer pain
10. Covi-Stix EUA application(approval in Mexico, Brazil and Europe...millions shipped to Mexico. WHO and Canada coming soon. DOD CRADA
11. Covi-Trace EUA application
12. Sofusa Enbrel phase 1b
13. Cynviloq (part of PSS lawsuit)
***PHASE 2 (13 programs)
1. Seprehvir Oncolytic virus
2. Covi-MSC EUA potential
3. Covi-AMG EUA potential DOD CRADA
4. COVIDROPS phase 2 US, UK and Mexico. EUA potential DOD CRADA
5. Covi-Track EUA pre-validation DOD CRADA
6. PD-L1 partnered
7. Herceptin delivery partnered
8. Abivertinib Lymphoma
9. Abivertinib Covid 19 EUA potential to prevent intubation Brazil and US.
10. Abivertinib prostate cancer ph.2 IND
11. Abivertinib Lupus ph.2 IND
12. Abivertinib hairy cell leukemia
13. CD47 partnered
***PHASE 1, IND filed or pre-IND (46+ programs)
1. Seprehvec Oncolytic Virus
2. CD 38 CAR-T ph.1
3. CEA CAR-T ph.1
4. CD38 DAR-T ph.1
5. BCMA DAR-T pre-IND
6. PD-L1(C/DAR-T) pre-IND
7. CyCART-19 partnered
8. Covi-GeneMab pre-IND $34 million DARPA funding
9. PD1-GeneMab pre-IND
10. ERT (Enzyme Replacement Therapy) several pre IND programs
11. IL2Teff pre-IND
12. IL2Treg pre-IND
13. Sofusa anti-PD1 and anti-CTLA4
14. TNF-a (Enbrel) ph.1
15. CTLA-4 (Yervoy)
16. CD47 ph.1 basket trial partnered
17. TROP2 IND granted in China...partnered.
18. BCMA ADC pre-IND
19. ROR1 ADC pre-IND
20. CD25 ADNAB pre-IND
21. CD20 ADNAB (Rituxan) IIT-ph.1
22. VEGF(Avastin) ADNAB IIT-ph.1
23. PD-L1 ADNAB pre-IND
24. VEGFR2 ADNAB pre-IND
25. CBD immune diseases pre-IND
26. CBD insomnia pre-IND
27. CBD Parkinsons pre-IND
28. CBD CNS diseases pre-IND
29. PD-L1 CAR-NK partnered
30. CD38 CAR-NK to be partnered
31. CD38 ADC AL Amyloidosis
32. AC0058 ph.1b lupus
33. AC0058 pre-IND MS
34. AC0939 pre-IND CNS indications
35. A166 HER2 ADC phase 1
36. Karolinska off-the-shelf DAR-NK pre-IND
37. Covid mRNA vaccine(Sofusa delivery)
38.low cost C1 based multivalent vaccine(rights to 60% of world population)...can this deal be expanded?
39. Salicyn-30 oral antiviral
40.MP18 oral antiviral MPro inhibitor
41.Combination oral antiviral drug cocktail
42.RESPISTIX Combination Covid/seasonal flu tests
43.Combination Covid/seasonal flu vaccine
44 advanced Animal Health subsidiary
45. 1,000,000+ small molecule library
46. Twenty quadrillion antibody library
FUNDING? Sorrento has invested wisely and has millions of shares of Celularity and ImmuneOncia. These are worth many hundreds of millions and the PSS binding arbitration could be settled with very large potential gains. It has many attractive programs to partner for upfront, milestone and royalty payments! The first of many EUA's are producing revenue in Mexico. Outstanding ABIVERTINIB(COVID) results in Brazil and US. Giant ABIVERTINIB centered partnership(s) coming soon! And SP-102 sales will begin in 2022 with multi-billion potential. Huge portfolio AND huge assets! Sorrento is in the early days of becoming(or being acquired by...) a Big Pharma!
I could be wrong...but I think the Dyadic deal is delayed because it is being EXPANDED!
FIVE (5) REASONS SORRENTO SHAREPRICE WILL RISE!
1. ABIVERTINIB $61 Billion global market partnership(s). There will be multi-billion upfront, milestone and royalty payments. And look to the partnership partners to become the eventual buyout actors!
2. SCILEX SPINOFF. SP-102 data is due next month. This new treatment could gross $6-10 billion annually. The partner is a wealthy Singapore based venture capital firm.
3. COVISTIX REVENUE STREAM. Sales are recording in Q4 of 2021 and will ramp up in Q1 of 2022. Europe, Central and South America, Canada, Japan and the US will follow.
4. COVI-AMG, COVIDROPS, COVI-MSC, SP-102, ABIVERTINIB(cancer and Covid) news is expected in Q1 2022 as are more EUA's. SP-102 and ABIVERTINIB revenue expected in 2H of 2022.
5. ORAL MP18 based PAN-COVID ANTI-VIRAL. A peer-reviewed publication was released showing strong pan-Covid activity (including Omicron). This could enter the clinic in Q1 or Q2. A world-wide development and marketing partner might be expected. Look for something better than Merck or Pfizer's drugs!
3 big reasons why Sorrento share price will increase dramatically.
1. ABIVERTINIB global $61 billion market partnership(s). This will be a multi-billion, worldwide, upfront, milestone and royalty deal. This alone will fund Sorrento's other 75 programs.
2. COVISTIX revenue stream. Sales are being recorded in Q4 of 2021 and will dramatically increase in Q1 of 2022. Europe, Central and South America, Canada and Japan will soon be on stream. Even the US may catch up!
3. In Q1 of 2022 there will be important trial results from COVI-AMG, COVIDROPS, COVI-MSC, SP-102 and ABIVERTINIB(NSCLC). There could be several more EUA's and marketing could begin for SP-102 and ABIVERTINIB in 2H of 2022.
Investors say "SHOW US THE MONEY"...and that will happen big time in 2022!
I was glad to see the new updated corporate presentation. https://investors.sorrentotherapeutics.com/static-files/f9f8b12e-6037-4b48-b919-6d99d417698a
And big funds are buying shares! Blackrock 20.8 million:Vanguard 15.5 million:State St. 12.3 million.
***PHASE 3, close to EUA or close to market (13 programs)
1. Abivertinib NSCLC NDA filed China
2. Abivertinib NSCLC ph.3 completed US
3. PD-L1 SCLC partnered.China NDA filed for cervical cancer.
4. Erbitux biosimilar
5. Xolair biosimilar
6. Remicade biosimilar(approved in China. SRNE holds ROW rights!)
7. SP-102 sciatica + back pain. Marketing in 2H 2022.
8. RTX Osteo Arthritis
9. RTX cancer pain
10. Covi-Stix EUA application(approval in Mexico, Brazil and Europe...millions shipped to Mexico. WHO and Canada coming soon. DOD CRADA
11. Covi-Trace EUA application
12. Sofusa Enbrel phase 1b
13. Cynviloq (part of PSS lawsuit)
***PHASE 2 (13 programs)
1. Seprehvir Oncolytic virus
2. Covi-MSC EUA potential
3. Covi-AMG EUA potential DOD CRADA
4. COVIDROPS phase 2 US, UK and Mexico. EUA potential DOD CRADA
5. Covi-Track EUA pre-validation DOD CRADA
6. PD-L1 partnered
7. Herceptin delivery partnered
8. Abivertinib Lymphoma
9. Abivertinib Covid 19 EUA potential to prevent intubation Brazil and US.
10. Abivertinib prostate cancer ph.2 IND
11. Abivertinib Lupus ph.2 IND
12. Abivertinib hairy cell leukemia
13. CD47 partnered
***PHASE 1, IND filed or pre-IND (46+ programs)
1. Seprehvec Oncolytic Virus
2. CD 38 CAR-T ph.1
3. CEA CAR-T ph.1
4. CD38 DAR-T ph.1
5. BCMA DAR-T pre-IND
6. PD-L1(C/DAR-T) pre-IND
7. CyCART-19 partnered
8. Covi-GeneMab pre-IND $34 million DARPA funding
9. PD1-GeneMab pre-IND
10. ERT (Enzyme Replacement Therapy) several pre IND programs
11. IL2Teff pre-IND
12. IL2Treg pre-IND
13. Sofusa anti-PD1 and anti-CTLA4
14. TNF-a (Enbrel) ph.1
15. CTLA-4 (Yervoy)
16. CD47 ph.1 basket trial partnered
17. TROP2 IND granted in China...partnered.
18. BCMA ADC pre-IND
19. ROR1 ADC pre-IND
20. CD25 ADNAB pre-IND
21. CD20 ADNAB (Rituxan) IIT-ph.1
22. VEGF(Avastin) ADNAB IIT-ph.1
23. PD-L1 ADNAB pre-IND
24. VEGFR2 ADNAB pre-IND
25. CBD immune diseases pre-IND
26. CBD insomnia pre-IND
27. CBD Parkinsons pre-IND
28. CBD CNS diseases pre-IND
29. PD-L1 CAR-NK partnered
30. CD38 CAR-NK to be partnered
31. CD38 ADC AL Amyloidosis
32. AC0058 ph.1b lupus
33. AC0058 pre-IND MS
34. AC0939 pre-IND CNS indications
35. A166 HER2 ADC phase 1
36. Karolinska off-the-shelf DAR-NK pre-IND
37. Covid mRNA vaccine(Sofusa delivery)
38.low cost C1 based multivalent vaccine(rights to 60% of world population)...can this deal be expanded?
39. Salicyn-30 oral antiviral
40.MP18 oral antiviral MPro inhibitor
41.Combination oral antiviral drug cocktail
42.RESPISTIX Combination Covid/seasonal flu tests
43.Combination Covid/seasonal flu vaccine
44 advanced Animal Health subsidiary
45. 1,000,000+ small molecule library
46. Twenty quadrillion antibody library
FUNDING? Sorrento has invested wisely and has millions of shares of Celularity and ImmuneOncia. These are worth many hundreds of millions and the PSS binding arbitration could be settled with very large potential gains. It has many attractive programs to partner for upfront, milestone and royalty payments! The first of many EUA's are producing revenue in Mexico. Outstanding ABIVERTINIB(COVID) results in Brazil and US. Giant ABIVERTINIB centered partnership(s) coming soon! And SP-102 sales will begin in 2022 with multi-billion potential. Huge portfolio AND huge assets! Sorrento is in the early days of becoming(or being acquired by...) a Big Pharma!